Design Therapeutics, Inc. (DSGN)
15.11
-0.14
(-0.92%)
USD |
NASDAQ |
Aug 28, 16:00
15.09
-0.02
(-0.13%)
After-Hours: 20:00
Design Therapeutics Shareholders Equity (Quarterly) : 201.86M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 201.86M |
| March 31, 2026 | 218.05M |
| December 31, 2025 | 212.50M |
| September 30, 2025 | 199.72M |
| June 30, 2025 | 213.04M |
| March 31, 2025 | 227.92M |
| December 31, 2024 | 242.10M |
| September 30, 2024 | 252.45M |
| June 30, 2024 | 261.24M |
| March 31, 2024 | 269.56M |
| December 31, 2023 | 277.69M |
| Date | Value |
|---|---|
| September 30, 2023 | 284.96M |
| June 30, 2023 | 296.80M |
| March 31, 2023 | 312.82M |
| December 31, 2022 | 327.31M |
| September 30, 2022 | 340.94M |
| June 30, 2022 | 357.16M |
| March 31, 2022 | 370.31M |
| December 31, 2021 | 382.13M |
| September 30, 2021 | 391.56M |
| June 30, 2021 | 401.60M |
| March 31, 2021 | 408.01M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Amgen, Inc. | 11.69B |
| AnaptysBio, Inc. | 12.75M |
| 4D Molecular Therapeutics, Inc. | 407.66M |
| Inhibrx Biosciences, Inc. | -52.98M |
| Agenus, Inc. | -199.08M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 215.13M |
| Total Liabilities (Quarterly) | 13.27M |
| Debt to Equity Ratio | 0.0132 |
| Current Ratio | 18.86 |
| Net Debt Paydown Yield | -0.01% |